TY - JOUR
T1 - Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and Is Associated with Worse Outcomes
AU - Pongor, Lőrinc Sándor
AU - Schultz, Christopher W.
AU - Rinaldi, Lorenzo
AU - Wangsa, Darawalee
AU - Redon, Christophe E.
AU - Takahashi, Nobuyuki
AU - Fialkoff, Gavriel
AU - Desai, Parth
AU - Zhang, Yang
AU - Burkett, Sandra
AU - Hermoni, Nadav
AU - Vilk, Noa
AU - Gutin, Jenia
AU - Gergely, Rona
AU - Zhao, Yongmei
AU - Nichols, Samantha
AU - Vilimas, Rasa
AU - Sciuto, Linda
AU - Graham, Chante
AU - Caravaca, Juan Manuel
AU - Turan, Sevilay
AU - Shen, Tsai Wei
AU - Rajapakse, Vinodh N.
AU - Kumar, Rajesh
AU - Upadhyay, Deep
AU - Kumar, Suresh
AU - Kim, Yoo Sun
AU - Roper, Nitin
AU - Tran, Bao
AU - Hewitt, Stephen M.
AU - Kleiner, David E.
AU - Aladjem, Mirit I.
AU - Friedman, Nir
AU - Hager, Gordon L.
AU - Pommier, Yves
AU - Ried, Thomas
AU - Thomas, Anish
N1 - Publisher Copyright:
© 2023 American Association for Cancer Research.
PY - 2023/4/3
Y1 - 2023/4/3
N2 - Small-cell lung cancer (SCLC) is an aggressive neuroendocrine lung cancer. Onco-genic MYC amplifications drive SCLC heterogeneity, but the genetic mechanisms of MYC amplification and phenotypic plasticity, characterized by neuroendocrine and nonneuroen-docrine cell states, are not known. Here, we integrate whole-genome sequencing, long-range optical mapping, single-cell DNA sequencing, and fluorescence in situ hybridization to find extrachromosomal DNA (ecDNA) as a primary source of SCLC oncogene amplifications and driver fusions. ecDNAs bring to proximity enhancer elements and oncogenes, creating SCLC transcription-amplifying units, driving exceptionally high MYC gene dosage. We demonstrate that cell-free nucleosome profiling can nonin-vasively detect ecDNA amplifications in plasma, facilitating its genome-wide interrogation in SCLC and other cancers. Altogether, our work provides the first comprehensive map of SCLC ecDNA and describes a new mechanism that governs MYC-driven SCLC heterogeneity. ecDNA-enabled transcriptional flexibility may explain the significantly worse survival outcomes of SCLC harboring complex ecDNA amplifications.
AB - Small-cell lung cancer (SCLC) is an aggressive neuroendocrine lung cancer. Onco-genic MYC amplifications drive SCLC heterogeneity, but the genetic mechanisms of MYC amplification and phenotypic plasticity, characterized by neuroendocrine and nonneuroen-docrine cell states, are not known. Here, we integrate whole-genome sequencing, long-range optical mapping, single-cell DNA sequencing, and fluorescence in situ hybridization to find extrachromosomal DNA (ecDNA) as a primary source of SCLC oncogene amplifications and driver fusions. ecDNAs bring to proximity enhancer elements and oncogenes, creating SCLC transcription-amplifying units, driving exceptionally high MYC gene dosage. We demonstrate that cell-free nucleosome profiling can nonin-vasively detect ecDNA amplifications in plasma, facilitating its genome-wide interrogation in SCLC and other cancers. Altogether, our work provides the first comprehensive map of SCLC ecDNA and describes a new mechanism that governs MYC-driven SCLC heterogeneity. ecDNA-enabled transcriptional flexibility may explain the significantly worse survival outcomes of SCLC harboring complex ecDNA amplifications.
UR - http://www.scopus.com/inward/record.url?scp=85149068807&partnerID=8YFLogxK
U2 - 10.1158/2159-8290.CD-22-0796
DO - 10.1158/2159-8290.CD-22-0796
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 36715552
AN - SCOPUS:85149068807
SN - 2159-8274
VL - 13
SP - 928
EP - 949
JO - Cancer Discovery
JF - Cancer Discovery
IS - 4
ER -